A 2026 iScience study found that 45 days of clomipramine improved spatial, working, and reference memory in female APP/PS1 Alzheimer’s-model mice, apparently by blocking the E3 ubiquitin ligase Itch rather than by clearing amyloid plaques.1 Research Highlights 45-day clomipramine signal: 6-month female APP/PS1 mice received 25 mg/kg clomipramine every other day for 45 days, then …
A 2025 longitudinal analysis of 1,528 older Chinese Americans by Chen et al. in the Journal of Prevention of Alzheimer’s Disease says something more specific than “stress causes Alzheimer’s”: it isn’t the count of stressors that tracks memory decline — it’s a latent trait the authors call stress internalization, a bundle of high perceived stress, …
Statins do not look like a dementia-prevention drug, but they do not look like a dementia hazard either. In 322,358 Kaiser Permanente Northern California patients followed for an average of 11.8 years, dementia diagnoses rose right after statins were started, then flattened: after the first year, the hazard ratio for Alzheimer’s disease and related dementias …
A 2026 PPMI analysis found that Parkinson’s patients with positive CSF α-synuclein seed amplification assay results kept gaining levodopa benefit over follow-up, while SAA-negative patients showed faster ON-medication motor progression than SAA-positive patients: 0.87 vs. 3.47 MDS-UPDRS Part III points/year in 183 matched SAA-positive and 40 SAA-negative patients.1 Research Highlights ON-state progression split sharply: SAA-positive …
A 2026 Australian ecological model found that 20-year-lagged cumulative population blood-lead burden was nonlinearly tied to motor neuron disease mortality (lead spline p = 0.00024), while national insecticide use did not independently explain the curve after adjustment (p = 0.39).1 That is a real lead signal, but it is still population-level evidence, not proof that …
A 2026 Molecular Psychiatry study found that RVI-AD, a structural-MRI score measuring how closely a person’s brain anatomy matches an Alzheimer’s disease pattern, predicted mild-cognitive-impairment conversion to dementia most strongly over the next 3 years: OR 2.16, 95% CI 1.81-2.57, p < 2e-16, AUC 0.70.1 Research Highlights Short-term conversion signal: in 965 ADNI participants with …
A 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both present: X-34 plaque area differed across IgG1, lecanemab, and Fc-silenced LALA-PG groups (P = 0.0003), 82E1 plaque area differed across groups (P < 0.0001), and microglia-deficient mice showed …